CN105343076A - Composition and application thereof in acute renal failure resisting drug - Google Patents
Composition and application thereof in acute renal failure resisting drug Download PDFInfo
- Publication number
- CN105343076A CN105343076A CN201510742196.6A CN201510742196A CN105343076A CN 105343076 A CN105343076 A CN 105343076A CN 201510742196 A CN201510742196 A CN 201510742196A CN 105343076 A CN105343076 A CN 105343076A
- Authority
- CN
- China
- Prior art keywords
- renal failure
- acute renal
- composition
- compositions
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the fields of organic synthesis and medicinal chemistry, and in particular relates to a composition, a preparation method and application of the composition in preparing an acute renal failure resisting drug. The invention discloses a composition and a preparation method thereof. Based upon pharmacological experiments, the composition disclosed by the invention has an effect on resisting the acute renal failure, so that the composition has the value of developing the acute renal failure resisting drug.
Description
Technical field
The present invention relates to organic synthesis and medicinal chemistry art, be specifically related to compositions, preparation method and its usage.
Background technology
Acute renal failure (AcuteRenalFailure, ARF) be the clinical syndrome caused by many reasons, be found in clinical departments patient, sickness rate is high and often have serious consequences, its feature is that (a few hours are to a couple of days) renal function sharply declines in a short time, clinical manifestation is acute oliguria (urine volume <400mLPd) or anuria (urine volume <100mLPd), in body, nitrogen matter metabolite is discharged and is produced obstacle, there is azotemia rapidly, water and electrolyte, acid base imbalance, and cause each system corresponding function imbalance of whole body.The principal element of acute renal failure is caused to be the sharply minimizing of renal blood flow, and the oxidative stress caused due to nephridial tissue ischemia and cell injury, finally cause the deterioration of renal tissue structural damage and function.There is no the generally acknowledged effective medicine for the treatment of acute renal failure clinically at present, only by correcting water-electrolyte balance, correcting the symptomatic treatment measures such as acidosis and improving symptom, the later stage also needs to maintain body function by hemodialysis.Improving kidney perfusion obstacle and alleviating in Renal tissues damage and have the clinical medicine of obvious curative effects rare.
From natural product, find compound or lead compound and carry out structural modification and obtain its derivant, thus the potential drug obtaining high-efficiency low-toxicity there is important value most.
The Compound I that the present invention relates to is one and delivers (AyumiOhsakietal. in 2011,2011.SalviskinoneA, aditerpenewithanewskeletonfromSalviaprzewalskii.Tetrahed ronLetters52 (2011) 1375 – 1377) compound, we have carried out structural modification to Compound I, obtain two new derivants and compound III and compound IV, and prepared compositions by compound III and compound IV and the anti-acute renal failure activity of said composition is evaluated, it is active that it has anti-acute renal failure.
Summary of the invention
The invention discloses a new compositions, said composition is made up of compound III and compound IV, and in said composition, the mass percent of compound III and compound IV is respectively 65% and 35%.
Compositions disclosed by the invention can make pharmaceutically acceptable salt or pharmaceutically acceptable carrier.
The object of this invention is to provide the purposes that compositions is used for the treatment of acute renal failure, namely for the preparation of the purposes for the treatment of acute renal failure medicine.
Compositions of the present invention has obvious therapeutical effect to acute renal failure disease.
Find that compositions can improve the function of kidney by our research.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Detailed description of the invention
The preparation of embodiment 1 compound S alviskinoneA
Document (the AyumiOhsakietal. that the people such as the preparation method reference AyumiOhsaki of compound S alviskinoneA (I) deliver, 2011.SalviskinoneA, aditerpenewithanewskeletonfromSalviaprzewalskii.Tetrahed ronLetters52 (2011) 1375 – 1377) method.
The synthesis of the O-bromoethyl derivant (II) of embodiment 2SalviskinoneA
By Compound I (312mg, 1.00mmol) be dissolved in 15mL benzene, add in solution tetrabutyl ammonium bromide (TBAB) (0.08g), 1,50% sodium hydroxide solution of 2-Bromofume (3.760g, 20.00mmol) and 6mL.Mixture stirs 12h at 35 degrees Celsius.After 12h, reactant liquor is poured in frozen water, use dichloromethane extraction twice immediately, merge organic phase solution.Then use water and saturated common salt water washing 4 times successively to organic phase solution, then use anhydrous sodium sulfate drying, last concentrating under reduced pressure is removed solvent and is obtained product crude product.Product crude product purification by silica gel column chromatography (mobile phase is: petroleum ether/acetone=100:1.5, v/v), collects brown concentrated elution band and flings to the brown ceramic powder (327mg, 78%) that namely solvent obtains Compound II per.
1HNMR(500MHz,DMSO-d
6)δ6.63(s,1H),6.37(s,1H),5.81(s,1H),4.51(s,2H),3.84(s,1H),3.79(s,2H),2.15(s,1H),2.04(s,1H),1.91(s,1H),1.65(s,1H),1.39(s,3H),1.08(s,6H),0.99(s,6H).
13CNMR(125MHz,DMSO-d6)δ188.07(s),183.70(s),154.38(s),147.57(s),140.21(s),136.40(s),134.71(s),131.25(s),128.40(s),118.83(s),72.12(s),45.49(s),37.54(s),33.58(s),31.78(s),26.17(s),25.12(s),24.66(s),23.51(s),23.17(s),22.65(s).
HRMS(ESI)m/z[M+H]
+calcdforC
22H
28BrO
3:419.1222；found419.1220.
The synthesis of O-(piperazinyl) ethyl derivative (III) of embodiment 3SalviskinoneA
Compound II per (209mg, 0.5mmol) is dissolved in the middle of 25mL acetonitrile, adds Anhydrous potassium carbonate (690mg wherein, 5.0mmol), potassium iodide (168mg, 1.0mmol) and Piperazine anhydrous (3446mg, 40mmol), mixture reflux 6h.After reaction terminates, reactant liquor is poured in frozen water, with equivalent dichloromethane extraction 3 times, merge organic facies.Organic facies after merging with water and saturated common salt water washing successively, then use anhydrous sodium sulfate drying, concentrating under reduced pressure is removed solvent and is obtained product crude product.Product crude product purification by silica gel column chromatography (mobile phase is: petroleum ether/acetone=100:1.5, v/v), collects brown concentrated elution band and flings to the Light brown solid (154.8mg, 73%) that namely solvent obtains compound III.
1HNMR(500MHz,DMSO-d6)δ6.57(s,1H),6.37(s,1H),5.81(s,1H),4.27(s,2H),3.84(s,1H),3.12(s,2H),2.69(s,4H),2.36(s,4H),2.14(s,1H),2.05(s,1H),1.94(s,1H),1.70(s,1H),1.35(s,3H),1.15(s,1H),1.07(s,6H),1.00(s,6H).
13CNMR(125MHz,DMSO-d6)δ188.23(s),183.96(s),154.74(s),148.03(s),140.77(s),136.56(s),134.97(s),131.61(s),128.86(s),119.35(s),69.37(s),54.95(s),54.52(s),45.97(s),45.84(s),37.68(s),33.82(s),26.51(s),25.61(s),25.25(s),23.65(s),23.41(s),22.99(s).
HRMS(ESI):m/z[M+H]
+calcdforC
26H
37N
2O
3:425.2804；found:425.2801。
The synthesis of O-(the 1H-tetrazole base) ethyl derivative (IV) of embodiment 4SalviskinoneA
By Compound II per (209mg, 0.5mmol) be dissolved in the middle of 20mL acetonitrile, add Anhydrous potassium carbonate (345mg wherein, 2.5mmol), potassium iodide (84mg, 0.5mmol) with 1H-tetrazole (1401mg, 20mmol), mixture reflux 10h.After reaction terminates, reactant liquor is poured in 25mL frozen water, with equivalent dichloromethane extraction 2 times, merge organic facies.Organic facies after merging with water and saturated common salt water washing successively, then use anhydrous sodium sulfate drying, concentrating under reduced pressure is removed solvent and is obtained product crude product.Because tautomerization, 1H-tetrazole base and 2H-tetrazole base two kinds of substitution products can be generated at reaction conditions.(mobile phase is product crude product purification by silica gel column chromatography: petroleum ether/acetone=100:1, v/v), collect yellow concentrated elution band, again elution band is concentrated, with purification by silica gel column chromatography (mobile phase is: petroleum ether/acetone=100:0.5, v/v), collect two flaxen elution bands successively, namely concentrated front 1 elution band obtains the yellow powder (85.7mg, 42%) of compound IV.
1HNMR(500MHz,Chloroform-d1)δ10.21(s,1H),6.53(d,J＝95.4Hz,1H),6.31(s,1H),5.73(s,1H),4.41(t,J＝7.8Hz,4H),4.04(s,1H),2.09(s,1H),1.98(s,1H),1.85(s,1H),1.59(s,1H),1.33(s,3H),1.02(s,6H),0.93(s,6H).
13CNMR(125MHz,DMSO-d6)δ188.01(s),183.52(s),154.09(s),147.15(s),144.60(s),140.11(s),136.23(s),134.42(s),130.84(s),127.86(s),118.73(s),66.79(s),46.45(s),45.42(s),37.35(s),33.27(s),25.74(s),24.62(s),24.60(s),23.32(s),22.86(s),22.22(s).
HRMS(ESI):m/z[M+H]
+calcdforC
23H
29N
4O
3:409.2240；found:409.2245。
Embodiment 5 compositions is to the therapeutical effect of acute renal failure rat
(1) experimental technique
The preparation of compositions: loaded by the powder of 35mg compound IV crossing 200 order nets after crossing the powder of the 65mg compound III of 200 order nets and grinding after grinding to mix in tubule with cover and with turbine stirring instrument and namely obtain 100mg compositions, obtains the solution of compositions by the compositions of this 100mg of water dissolution during use.
Intramuscular injection glycerol is adopted to cause Acute Renal Failure Rats animal model.Select the healthy male SD rat 30 of 180 ~ 220g, be divided into 5 groups at random: sham operated rats (intramuscular injection normal saline); Model group (intramuscular injection glycerol); Administration intervention group (compositions, compound III or compound IV 0.6mg/Kg, intramuscular injection glycerol), each group rat tail vein injection saline or treat reagent thing immediately after glycerol modeling, is administered once after 12 and 24 hours again.
(2) observation index
Metabolic cage collection twenty-four-hour urine is put into after the administration of rat last or normal saline, stay latter 6 hours of urine with 4% chloral hydrate intraperitoneal injection of anesthesia, adopt laser Doppler flowmetry to measure after modeling and bilateral renal blood flow after treatment, average as single animal renal blood flow; Get blood and prepare serum, measure blood BUN and Cre (all by the operation of test kit description).
(3) experimental result
1. compositions can increase acute renal failure Mouse Kidney blood flow
Compositions significantly can increase acute renal failure Mouse Kidney blood flow, and compound III and compound IV act on without this.
Table 1 compositions is on the impact of acute renal failure Mouse Kidney blood flow
* P<0.05vs acute renal failure model group
2. compositions is to the protective effect of acute renal failure Mouse Kidney function tool
Acute renal failure rat intravenous injection normal saline is after 24 hours, and serum BUN and Cre is in table 2.Acute renal failure model group, apparently higher than sham operated rats, illustrates that model group animal renal function injury is serious.Compositions can improve the renal function (P<0.05) of acute renal failure rat, and compound III and compound IV act on without this.In table 2.
The each rats in test groups renal function index of table 2 compares
* P<0.05vs acute renal failure model group
Conclusion: compositions can protect the function of kidney, can be used for preparing anti-acute renal failure medicine.And compound III and compound IV can not protect kidney, should not be used to prepare anti-acute renal failure medicine.
The preparation of embodiment 6 composition tablet involved in the present invention
Get 2 grams of compositionss, add the customary adjuvant 18 grams preparing tablet, mixing, conventional tablet presses makes 100.
The preparation of embodiment 7 composition capsule involved in the present invention
Get 2 grams of compositionss, add prepare capsule customary adjuvant as starch 18 grams, mixing, encapsulatedly makes 100.
Claims (6)
1. a compositions, it is characterized by said composition and be made up of compound III and compound IV, in said composition, the mass percent of compound III and compound IV is respectively 65% and 35%,
2. the preparation method of compositions as claimed in claim 1, is characterized by: the powder of compound III and the powder of compound IV are respectively 65% and 35% according to mass percent and fully mix.
3. the application of compositions as claimed in claim 1 in treatment acute renal failure medicine.
4. the application of compositions as claimed in claim 3 in treatment acute renal failure medicine, is characterized by: the reduction of the renal blood flow amount caused by described composition for improved acute renal failure.
5. the application of compositions as claimed in claim 3 in treatment acute renal failure medicine, is characterized by: the rising of the serum BUN that described composition for improved acute renal failure causes.
6. the application of compositions as claimed in claim 3 in treatment acute renal failure medicine, is characterized by: the rising of the change of serum C re that described composition for improved acute renal failure causes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510742196.6A CN105343076A (en) | 2015-11-04 | 2015-11-04 | Composition and application thereof in acute renal failure resisting drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510742196.6A CN105343076A (en) | 2015-11-04 | 2015-11-04 | Composition and application thereof in acute renal failure resisting drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105343076A true CN105343076A (en) | 2016-02-24 |
Family
ID=55319238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510742196.6A Pending CN105343076A (en) | 2015-11-04 | 2015-11-04 | Composition and application thereof in acute renal failure resisting drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105343076A (en) |
-
2015
- 2015-11-04 CN CN201510742196.6A patent/CN105343076A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| AYUMI OHSAKI等: "salviskinone A, a diterpene with a new skeleton from salvia przewalskii", 《TETRAHEDRON LETTERS》 * |
| 曹译心等: "丹参酮IIA对急性肾功能衰竭大鼠肾脏的保护作用", 《四川解剖学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104083383B (en) | The application in preparing anti-acute renal failure medicine of O-(piperidyl) ethyl derivative of Cleistanone Cleistanone | |
| CN104095856B (en) | The application in preparing anti-acute renal failure medicine of the diethylamine derivative of Cleistanone Cleistanone | |
| CN105343082A (en) | Composition and application of composition in medicines for resisting acute renal failure | |
| CN105287585A (en) | Composition and application of composition in medicine for resisting acute renal failure | |
| CN105193793A (en) | Composition and application thereof in anti-ARF (Acute Renal Failure) drugs | |
| CN105267195A (en) | Composition and application of composition to acute renal failure resisting drugs | |
| CN105343076A (en) | Composition and application thereof in acute renal failure resisting drug | |
| CN104434929B (en) | The application in preparing anti-acute renal failure medicine of O-(piperazinyl) ethyl derivative of Cleistanone | |
| CN105287463A (en) | Composition and application thereof to acute renal failure (ARF) resistant medicines | |
| CN105250289A (en) | Composition and application thereof to acute renal failure (ARF) resistant medicines | |
| CN104784190A (en) | Application of O-(benzimidazolyl) ethyl derivative of cleistanone in preparation of medicine for resisting acute renal failure | |
| CN105125556A (en) | Composition and application thereof in drugs for resisting acute renal failure | |
| CN105213395A (en) | Compositions and the application in anti-acute renal failure medicine thereof | |
| CN105250307A (en) | Composition and application thereof to acute renal failure (ARF) resistant medicines | |
| CN105030773A (en) | Composition 64083001030526 and application thereof in acute renal failure resisting medicine | |
| CN105380950A (en) | Composition and application thereof to acute renal failure resistant drug | |
| CN104906091A (en) | Application of O-(diethylin)ethyl derivative of Daphmalenine A in preparing acute renal failure resisting drugs | |
| CN106822107A (en) | The imidazole radicals of Psiguadial A and two hydroxyethylamine derivative compositions are used for anti-acute renal failure | |
| CN106038542A (en) | Application of composition of Artalbicacid derivatives in preparation of acute renal failure resistant drugs | |
| CN106074534A (en) | The composition of Ah draw'sing Bick acid triazolyl and 1H tetrazole radical derivative is for preparing anti-acute renal failure medicine | |
| CN104784176A (en) | Application of derivative of Daphmalenine A in preparation of acute renal failure resisting drugs | |
| CN104666310A (en) | Application of O-(triazolyl) ethyl derivative of Cleistanone in preparation of medicine resistant to acute renal failure | |
| CN105920005A (en) | Application of composition of piperazinyl and imidazolyl derivatives of Virosaine A in acute renal failure resisting medicines | |
| CN105853436A (en) | Application of composition of pyrrolidine derivative and morpholinyl derivative of Virosaine A to medicine against acute renal failure | |
| CN105596332A (en) | Composition, and applications thereof in preparation of drugs used for treating acute renal failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160224 |